x
CME-Tagline

Live Q&A: Bench to Bedside OnDemand: The Growing (Anti)body of Evidence for the Treatment of Mild-to-Moderate COVID-19

CMEO Webcast

Live Webcast: Wednesday, May 19, 2021
7:00 PM - 7:30 PM ET

This activity offers CE credit for:

  1. Physicians (CME)
  2. Pharmacists (ACPE)
  3. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Thursday, May 19, 2022

Faculty


Peter Chen, MD Peter Chen, MD 
Professor of Medicine and Biomedical Sciences
Director, Division of Pulmonary and Critical Care Medicine
Cedars-Sinai Medical Center
Los Angeles, CA

Statement of Need

The novel SARS-CoV-2 virus caused the rapid global spread of COVID-19, and while coronavirus is often mild and self-limiting, approximately 10% of mild SARS-CoV-2 infections progress to severe symptoms, including respiratory distress syndrome, and up to 20% of symptomatic patients develop critical disease with clinical complications including pneumonia and hyper-inflammation. Several repurposed drugs have been used to treat patients hospitalized with serious COVID-19 disease, with neutralizing monoclonal antibodies (nAbs) being one of the first therapies offered by the FDA. But despite promising results, the demand for treatment for mild-to-moderate COVID-19 has not met expectations, as many health care professionals may not be familiar with or aware that preventative treatments are available for mild-to-moderate COVID-19.

This live question-and-answer session is your opportunity to ask our faculty your questions based on the CME Outfitters Live webcast taking place on May 12, 2021 from 12:00 - 1:30 PM ET.

Unable to attend the live program? Access the OnDemand version of the webcast - available within 48 hours of the live broadcast - and join us for this second live Q&A session with our expert faculty.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Integrate screening assessments for the early and accurate diagnosis of mild-to-moderate COVID-19 to guide treatment decision-making in high-risk patient groups.
  • Apply the latest data on the efficacy and safety of nAb therapies to treatment decisions for patients with mild-to-moderate COVID-19.
  • Implement strategies to address knowledge and practice barriers to patient access to infusion service for nAb therapy.

The following learning objectives pertain only to those requesting CNE credit:

  • Summarize screening assessments used for the early and accurate diagnosis of mild-to-moderate COVID-19 to guide treatment decision-making in high-risk patient groups.
  • Discuss the latest data on the efficacy and safety of nAb therapies to treatment decisions for patients with mild-to-moderate COVID-19.
  • Describe strategies to address knowledge and practice barriers to patient access to infusion service for nAb therapy.

Financial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com

Target Audience

Physicians, PAs, nurse practitioners, nurses, infusion center nurses, and pharmacists

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this live activity for a maximum of .5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPE Credit (Pharmacists):
ACPE CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. .5 contact hour (0.05 CEUs). Universal Activity Number:
Live: 0376-0000-21-077-L01-P

Type: knowledge-based

Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Note to PAs: PAs may claim a maximum of .5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

Credit request forms and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately. This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Chen reports that he is on the advisory board for Eli Lilly and Company.

Maria Glukhovsky, PharmD (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


This document was last modified on:

TVQ-136-051921-11